News brief­ing: Pfiz­er on track to ear­ly '22 piv­otal read­out on he­mo­phil­ia A; Co­di­ak scales back IPO ex­pec­ta­tions

Pfiz­er and Sang­amo have dosed their first pa­tient in the Phase III gene ther­a­py tri­al of giroc­toco­gene fitel­par­vovec (SB-525) for he­mo­phil­ia A. Re­searchers will be fol­low­ing the ex­pe­ri­ences of pa­tients for 12 months af­ter dose, check­ing on safe­ty, ef­fi­ca­cy and dura­bil­i­ty. The move comes on the heels of a ma­jor set­back at ri­val Bio­Marin, which re­ceived a re­jec­tion let­ter from the FDA, which de­mand­ed more proof of dura­bil­i­ty — a sore point among some of the an­a­lysts track­ing the pro­gram.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN